- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01167127
Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain
February 11, 2013 updated by: Mundipharma Pharmaceuticals B.V.
An Open Study to Observe OXN Treatment for Patients With Moderate to Severe Non-malignant Pain
The main objective of the study is to observe the OXN treatment of patients with moderate to severe non-malignant pain in daily clinical practise with respect to pain relief and bowel function.
Patients who have insufficient pain relief and/or unacceptable side effects with the previous analgesic treatment WHO step 1 or 2 and require around-the-clock opioid therapy can be included in the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients will receive OXN for 3 weeks in the first phase (core phase) and in the second phase (extension phase) they will receive OXN as is daily clinical practice until reimbursement of OXN in the Netherlands or until discontinuation on request of the patient.
Study Type
Interventional
Enrollment (Actual)
113
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leeuwarden, Netherlands
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients at least 18 years or older with moderate to severe non-malignant pain who are willing to provide written informed consent.
- Females less than one year post-menopausal must have a negative urine pregnancy test recorded at the screening visit, be non-lactating, and willing to use adequate and reliable contraception throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.
- Patients with documented history of moderate to severe, non-malignant pain treated with WHO step I or II analgesics with insufficient pain relief and/or unacceptable side effects that requires around-the-clock opioid therapy (starting dose of oxycodone over 20 mg/day) and are likely to benefit from WHO step III opioid therapy for the duration of the study. Patients must be willing to discontinue their current analgesics (opioids and co-analgesics like anti-depressants and anti-epileptics).
- Patients are willing to discontinue pre study laxative medication.
- Patients taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose and regimen throughout the study, and in the investigators opinion are willing and able to maintain adequate hydration.
- Patients willing and able to participate in all aspects of the study, including use of medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, informed consent.
Exclusion Criteria:
- Any history of hypersensitivity to oxycodone, naloxone, related products, and other ingredients.
- Patients that require a dose over 20 mg/day oxycodone at the start of the study.
- Active alcohol or drug abuse and/or history of opioid abuse.
- Evidence of clinically significant cardiovascular, renal, hepatic, or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the patient at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results.
- In the investigator's opinion, patients who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication.
- Patients receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine).
- Patients with uncontrolled seizures or convulsive disorder.
- Patients who have a confirmed diagnosis of ongoing irritable bowel syndrome.
- Patients with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc).
- Patients who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry.
- Surgery completed prior to the start of the study, or planned surgery during the study that would influence pain or bowel function during the study or preclude completion of the study.
- Patients presently taking, or who have taken, naloxone <30 days prior to the start of the study.
- Patients suffering from diarrhoea and/or opioid withdrawal.
- Patients with any situation in which opioids are contra-indicated, severe respiratory depression with hypoxia and/or hypercapnia, severe obstructive pulmonary disease, cor pulmonale, severe bronchial asthma, paralytic ileus.
- Patients with myxodema, hypothyroidism, Addisons disease, increase of intracranial pressure and/or epilepsy (see also exclusion criteria 7).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Tablet
OXN tablet, oral BID, flexible dose design
|
OXN Tablet, oral, BID, flexible dose design
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Pain Relief
|
The Pain relief (NAS, 0-100) and the Bowel Function Index (BFI), 3 questions, both at week 1-4 of the core study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
Bowel movement
|
Bowel movement, 2 questions, and evaluation of laxative use, both at week 1-4 of the core study.
Quality of Life (EQ-5D), 5 questions, at week 1 and 4 of the core study.
The patient preference of OXN treatment compared to previous WHO step I or II analgesics with respect to overall treatment, measured at 5 categories, at Week 2, 3, 4 of the core study (core study Week 1-4).
The patient preference of OXN treatment compared to previous WHO step I or II analgesics with respect to quality of life, measured at 5 categories, at Week 2, 3, 4 of the core study (core study Week 1-4)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
April 1, 2011
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
July 20, 2010
First Submitted That Met QC Criteria
July 21, 2010
First Posted (Estimate)
July 22, 2010
Study Record Updates
Last Update Posted (Estimate)
February 12, 2013
Last Update Submitted That Met QC Criteria
February 11, 2013
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXN3504
- 2008-007013-71 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
-
Mundipharma Research GmbH & Co KGCompletedChronic OsteoarthritisSpain, Belgium, Finland, Czechia, Germany, Hungary
-
Mundipharma Research GmbH & Co KGCompletedSubjects With Moderate to Severe, Chronic Nonmalignant Pain
-
Mundipharma Research GmbH & Co KGCompletedPain | ConstipationUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Mundipharma (China) Pharmaceutical Co. LtdCompleted
-
Kati JärveläCompletedPostoperative Pain | Opioid Related DisordersFinland
-
Mundipharma Research GmbH & Co KGCompleted
-
Mundipharma Research GmbH & Co KGCompletedParkinson's Disease With Severe PainUnited Kingdom, Spain, Germany, Hungary, Czech Republic, Poland, Romania
-
Mundipharma Research GmbH & Co KGCompletedPain | Interstitial Cystitis | Painful Bladder SyndromePoland, Germany, Hungary, Czechia, United Kingdom
-
Mundipharma Research GmbH & Co KGCompletedModerate to Severe Idiopathic RLS With Daytime SymptomsSpain, Sweden, Germany